Cargando…

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease

INTRODUCTION: We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare. METHODS: Individuals with IBD we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markovinović, Ante, Quan, Joshua, Herauf, Michelle, Hracs, Lindsay, Windsor, Joseph W., Sharifi, Nastaran, Coward, Stephanie, Caplan, Léa, Gorospe, Julia, Ernest-Suarez, Kenneth, Ma, Christopher, Panaccione, Remo, Ingram, Richard J.M., Kanji, Jamil N., Tipples, Graham, Holodinsky, Jessalyn K., Bernstein, Charles N., Mahoney, Douglas J., Bernatsky, Sasha, Benchimol, Eric I., Kaplan, Gilaad G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453345/ https://www.ncbi.nlm.nih.gov/pubmed/37216598 http://dx.doi.org/10.14309/ajg.0000000000002337

Ejemplares similares

Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2022)

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2023)

A170 ADVERSE EVENTS & SEROLOGICAL RESPONSES FOLLOWING SARS-COV-2 VACCINATION IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Markovinovic, A, et al.
Publicado: (2023)

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study
por: Kaplan, Gilaad G, et al.
Publicado: (2022)

654: A THIRD DOSE OF SARS-COV-2 VACCINE YIELDS HIGH ANTIBODY LEVELS COMPARED TO TWO DOSE VACCINATION SCHEDULE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Quan, Joshua, et al.
Publicado: (2022)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

A195 DURABILITY OF SEROLOGICAL RESPONSES AFTER SECOND, THIRD AND FOURTH DOSE OF SARS-COV-2 VACCINATION IN INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Sharifi, N, et al.
Publicado: (2023)

SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

A193 DEMOGRAPHIC, SOCIAL AND OCCUPATIONAL FACTORS THAT PREVENTED EXPOSURE TO SARS-COV-2 IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: A PROSPECTIVE COHORT STUDY
por: Caplan, L N, et al.
Publicado: (2023)

Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada
por: Kuenzig, M Ellen, et al.
Publicado: (2022)

Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study
por: Buie, Michael J, et al.
Publicado: (2023)

A169 THE DIRECT COSTS OF INFLAMMATORY BOWEL DISEASE IN CANADA: A POPULATION-BASED ANALYSIS OF HISTORICAL AND CURRENT COSTS
por: Coward, S, et al.
Publicado: (2023)

A210 THE BURDEN OF IBD HOSPITALIZATION IN CANADA: AN ASSESSMENT OF THE CURRENT AND FUTURE BURDEN IN A NATION-WIDE ANALYSIS
por: Coward, S, et al.
Publicado: (2023)

A35 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS
por: Coward, S, et al.
Publicado: (2023)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications
por: Targownik, Laura E, et al.
Publicado: (2021)

Smoking Is Associated with an Increased Risk for Surgery in Diverticulitis: A Case Control Study
por: Diamant, Michael J., et al.
Publicado: (2016)

The Role of Bowel Ultrasound in Detecting Subclinical Inflammation in Pregnant Women with Crohn’s Disease
por: Leung, Yvette, et al.
Publicado: (2019)

The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology
por: Kaplan, Gilaad G, et al.
Publicado: (2019)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations
por: Murthy, Sanjay K, et al.
Publicado: (2021)

The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta
por: Kaplan, Gilaad G, et al.
Publicado: (2020)

Fr099 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC.
por: Olayinka, Lily, et al.
Publicado: (2021)

Association between Air Pollution and the Development of Rheumatic Disease: A Systematic Review
por: Sun, Gavin, et al.
Publicado: (2016)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology—The Trends of Disease Over Time
por: Coward, Stephanie, et al.
Publicado: (2021)

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
por: Ma, Christopher, et al.
Publicado: (2017)

A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
por: Cooper, J, et al.
Publicado: (2022)

Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
por: Widdifield, Jessica, et al.
Publicado: (2022)

Testing the Usability of a Software for Geospatial and Transport Modeling in Acute Stroke Service Planning
por: Holodinsky, Jessalyn K., et al.
Publicado: (2019)

Comparing regression modeling strategies for predicting hometime
por: Holodinsky, Jessalyn K., et al.
Publicado: (2021)

Using random forests to model 90-day hometime in people with stroke
por: Holodinsky, Jessalyn K., et al.
Publicado: (2021)

Optimal Transport Scenario With Rotary Air Transport for Access to Endovascular Therapy Considering Patient Outcomes and Cost: A Modeling Study
por: Wheaton, Ashlee, et al.
Publicado: (2021)

The 2023 Impact of Inflammatory Bowel Disease in Canada: Epidemiology of IBD
por: Coward, Stephanie, et al.
Publicado: (2023)

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy
por: Kaplan, Gilaad G, et al.
Publicado: (2021)

Fr098 IMPACT OF COVID-19 PANDEMIC IN IBD PATIENT CARE
por: Dahiya, Monica, et al.
Publicado: (2021)

The Impact of the COVID-19 Pandemic on IBD Care in Alberta: Patient and Provider Perspectives
por: Dahiya, Monica, et al.
Publicado: (2022)

A188 INFORMING IMMUNOCOMPROMISED POPULATIONS: AN EFFECTIVE AND EFFICIENT COVID-19 KNOWLEDGE TRANSLATION STRATEGY
por: Windsor, J W, et al.
Publicado: (2023)

Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration
por: Kuenzig, M. Ellen, et al.
Publicado: (2016)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

Effect of not vortexing nasopharyngeal and throat swabs on SARS-CoV-2 nucleic acid detection: A pilot study
por: Kanji, Jamil N., et al.
Publicado: (2022)

Declining Corticosteroid Use for Inflammatory Bowel Disease Across Alberta: A Population-Based Cohort Study
por: Seow, Cynthia H, et al.
Publicado: (2022)

The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary
por: Windsor, Joseph W, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlfq1bg17bfmm4ou832qfte573